Zakaria Y Abd Elmageed1, Andrew B Sholl2, Koji Tsumagari3, Zaid Al-Qurayshi3, Fulvio Basolo4, Krzysztof Moroz2, A Hamid Boulares5, Paul Friedlander6, Paulo Miccoli4, Emad Kandil7. 1. Department of Surgery, Tulane University School of Medicine, New Orleans, LA; Department of Otolaryngology, Tulane University School of Medicine, New Orleans, LA. 2. Department of Pathology, Tulane University School of Medicine, New Orleans, LA. 3. Department of Surgery, Tulane University School of Medicine, New Orleans, LA. 4. Department of Surgical, Medical, Molecular and Critical Area Pathology, Università degli Studi di Pisa, Pisa, Italy. 5. Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, LA. 6. Department of Otolaryngology, Tulane University School of Medicine, New Orleans, LA. 7. Department of Surgery, Tulane University School of Medicine, New Orleans, LA. Electronic address: ekandil@tulane.edu.
Abstract
BACKGROUND: BRAFV600E mutation has been investigated by immunohistochemistry and has shown high sensitivity and specificity. We aim to investigate the accuracy of immunohistochemistry versus molecular testing of BRAFV600E in papillary thyroid cancer using a large number of polymerase chain reaction-positive BRAFV600E papillary thyroid cancer tissues. METHODS: We stained 130 formalin-fixed papillary thyroid cancer specimens using the VE1 antibody: 100 BRAFV600E positive and 30 BRAFV600E negative confirmed by PCR. The sensitivity, specificity, and predictive values of the antibody were assessed. RESULTS: Immunohistochemistry of BRAFV600E showed 98.0% sensitivity, 93.3% specificity, and positive and negative predictive values of 98.0% and 93.3%, respectively. Of 100 patients with BRAFV600E PCR-positive samples, 97 (97.0%) had cytoplasmic weak (4.0%), moderate (17.0%), and strong (76.0%) immunostaining. In BRAFV600E PCR-negative samples, cytoplasmic staining was not detected in 93.3% (28/30) of papillary thyroid cancer tissues. The receiver operating characteristic curve demonstrated a high validity and comparable immunohistochemistry method (area under the curve = 98.8%) compared with PCR testing. CONCLUSION: The use of VE1 immunohistochemistry for the detection of BRAFV600E in papillary thyroid cancer tissues is a clinically applicable method with high specificity, sensitivity, and positive and negative predictive values. The reliable use of BRAFV600E immunohistochemistry should promulgate the routine use of this method for BRAFV600E detection in papillary thyroid cancer tissues.
BACKGROUND:BRAFV600E mutation has been investigated by immunohistochemistry and has shown high sensitivity and specificity. We aim to investigate the accuracy of immunohistochemistry versus molecular testing of BRAFV600E in papillary thyroid cancer using a large number of polymerase chain reaction-positive BRAFV600Epapillary thyroid cancer tissues. METHODS: We stained 130 formalin-fixed papillary thyroid cancer specimens using the VE1 antibody: 100 BRAFV600E positive and 30 BRAFV600E negative confirmed by PCR. The sensitivity, specificity, and predictive values of the antibody were assessed. RESULTS: Immunohistochemistry of BRAFV600E showed 98.0% sensitivity, 93.3% specificity, and positive and negative predictive values of 98.0% and 93.3%, respectively. Of 100 patients with BRAFV600E PCR-positive samples, 97 (97.0%) had cytoplasmic weak (4.0%), moderate (17.0%), and strong (76.0%) immunostaining. In BRAFV600E PCR-negative samples, cytoplasmic staining was not detected in 93.3% (28/30) of papillary thyroid cancer tissues. The receiver operating characteristic curve demonstrated a high validity and comparable immunohistochemistry method (area under the curve = 98.8%) compared with PCR testing. CONCLUSION: The use of VE1 immunohistochemistry for the detection of BRAFV600E in papillary thyroid cancer tissues is a clinically applicable method with high specificity, sensitivity, and positive and negative predictive values. The reliable use of BRAFV600E immunohistochemistry should promulgate the routine use of this method for BRAFV600E detection in papillary thyroid cancer tissues.
Authors: Mourad Zerfaoui; Koji Tsumagari; Eman Toraih; Youssef Errami; Emmanuelle Ruiz; Mohammed Sohail M Elaasar; Moroz Krzysztof; Andrew B Sholl; Sameh Magdeldin; Mohamed Soudy; Zakaria Y Abd Elmageed; A Hamid Boulares; Emad Kandil Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942
Authors: Koji Tsumagari; Zakaria Y Abd Elmageed; Andrew B Sholl; Erik A Green; Saboori Sobti; Abdul Razzaq Khan; Abdulrahman Kandil; Fadi Murad; Paul Friedlander; A Hamid Boulares; Emad Kandil Journal: Endocr Relat Cancer Date: 2018-01 Impact factor: 5.900
Authors: Shaimaa A Gad; Hamdy E A Ali; Rofaida Gaballa; Rania M Abdelsalam; Mourad Zerfaoui; Hamed I Ali; Salwa H Salama; Sanaa A Kenawy; Emad Kandil; Zakaria Y Abd Elmageed Journal: Sci Rep Date: 2019-10-02 Impact factor: 4.379